Endocrinology-metabolism / Original Article
Aromatase inhibitor use is a risk factor of carotid plaque presence in endocrine-responsive breast cancer patients
Da Hea Seo, Yongin Cho, Sujin Lee, Seho Park, Seung-Il Kim, Byeong Woo Park, Yumie Rhee
Korean J Intern Med. 2019;34(3):579-587. Published online August 25, 2017
Background/Aims: The aromatase inhibitors (AIs) are well known anti-hormonal therapy in endocrine-responsive breast cancer patients. It can lead to dyslipidemia and be the risk factor of cardiovascular disease due to low estrogen level. However, some recent studies comparing AIs with placebo have sh..
|